enGene Holdings Stock Plunge Tests Major Private Equity Backers
A sharp 16% weekly decline in enGene Holdings' share price puts significant pressure on its largest shareholder group—private equity firms controlling nearly half the company—raising questions about strategy and future direction amid broader market volatility.